US20040107006A1 - Resorbable implant materials - Google Patents

Resorbable implant materials Download PDF

Info

Publication number
US20040107006A1
US20040107006A1 US10/722,034 US72203403A US2004107006A1 US 20040107006 A1 US20040107006 A1 US 20040107006A1 US 72203403 A US72203403 A US 72203403A US 2004107006 A1 US2004107006 A1 US 2004107006A1
Authority
US
United States
Prior art keywords
tissue
material
alkylating agent
material according
resorbable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/722,034
Inventor
Ralph Francis
Qing Zhao
Amy Desmith
B. Oray
Original Assignee
Francis Ralph T.
Zhao Qing Hong
Amy Desmith
Oray B. Nicholas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/396,279 priority Critical patent/US6312474B1/en
Priority to PCT/US2000/025234 priority patent/WO2001019423A1/en
Priority to US10/099,425 priority patent/US6652594B2/en
Application filed by Francis Ralph T., Zhao Qing Hong, Amy Desmith, Oray B. Nicholas filed Critical Francis Ralph T.
Priority to US10/722,034 priority patent/US20040107006A1/en
Publication of US20040107006A1 publication Critical patent/US20040107006A1/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24Collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/362Skin, e.g. dermal papillae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3629Intestinal tissue, e.g. small intestinal submucosa
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/043Proteins; Polypeptides; Degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/043Proteins; Polypeptides; Degradation products thereof
    • A61L31/044Collagen

Abstract

A non-crosslinked, decellularized and purified mammalian tissue (e.g., bovine pericardium) having particular use as an implantable resorbable material. The material is treated by alkylating its primary amine groups in a manner sufficient to reduce the antigenicity of the tissue, permitting the treated tissue to be used in vivo and without crosslinking, and in turn, permitting it to be resorbable. The material can be used in surgical repair of soft tissue deficiencies for a certain period of time while the implant itself is gradually remodeled or absorbed by the host. Also provided are a method of preparing such a material, as well as a method of using such a material for surgical repair.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • The present application is a continuation of patent application having U.S. Ser. No. 10/099,425, filed 14 Mar. 2002, which is a continuation of and claims priority to International Application No. PCT/US00/25234 (published as International Publication No. WO 01/19423), filed 14 Sep. 2000 and designating the United States, which in turn claims priority from patent application having U.S. Ser. No. 09/396,279, filed 15 Sep. 1999, the entire disclosure of which is incorporated herein by reference.[0001]
  • TECHNICAL FIELD
  • The invention relates to materials for the use as implants within the body, and in particular, to resorbable and remodelable materials for such use. [0002]
  • BACKGROUND OF THE INVENTION
  • Various resorbable (occasionally referred to as absorbable or “remodelable”) materials presently exist for use in prosthetic applications, e.g., as patches, implants and/or as components of prosthetic devices. [0003]
  • Synthetic resorbable materials made from the polyesters, polylactide and polyglycolide, for example, have found use in various fields of medicine (See, e.g., Ashammaki, N. A., J. Biomed. Mater. Res., 33: 297-303; 1996). Versions of these materials exist commercially under the tradenames Vicryl® (Ethicon, Inc.) and Dexon® (Davis & Geck, Inc.). The gradual decomposition of these polymers is facilitated by hydrolysis, and catalyzed by biochemical action of the host tissues (Hanbrough, J. F., et al., J. Burn Care Rehab., 14: 485-494; 1993). These materials may be produced as membranes or as woven mesh in the case of producing resorbable suture. [0004]
  • While synthetic resorbable materials are a rather recent phenomenon, collagenous materials have been used as prosthetic grafting for many years; as in the case of lyophilized human dura, dating back to 1954. As a common practice for several years, such collagenous materials have been crosslinked with an agent such as glutaraldehyde, in order to diminish the antigenicity of a xenograft while increasing its resistance to enzymatic degradation produced by host tissue responses (Gratzer, P. F., et al., J. Biomed. Mater. Res., 31: 533-543; 1996). Polyepoxy compounds have also been used for such purposes, however are more stable with regard to the resulting alkylated amines in the collagen (Sung, H-W., et al., J. Biomater. Sci. Polymer Edn., 8: 587-600; 1997). While crosslinked tissues work well as long-term implants, they are not resorbable and as such, do not promote host tissue remodeling, or in turn, the eventual replacement of a graft by the body itself. [0005]
  • Aesculap AG & Co. (B. Braun Surgical) offers products under the tradename Lyoplant®, in the form of a bovine pericardium-based resorbable replacement for dura mater. Lyoplant® is produced by a process that involves mechanical removal of adherent fat and connective tissue, chemical treatment to inactivate enzymes and potential pathogens, freeze-drying, cutting to various sizes, packaging and terminal sterilization with ethylene oxide. The product is indicated to be used for covering cerebral and cerebellar dural defects, for decompressive duraplasty in cases of increased intracranial pressure, for covering spinal dural defects and for spinal decompressive duraplasty. This material has been observed to be fully remodeled within one year after implant. [0006]
  • Tutogen Medical, Inc. provides processed pericardium products under the tradename Tutoplast®, in the form of a solvent-dehydrated, gamma-irradiated preserved human pericardium. The processing of Tutoplast® tissue involves thorough cleaning, processing, dehydration and preservation. The process is said to leave no deleterious residue and minimizes antigenic potential. Collagenous connective tissue with multidirectional fibers retains the mechanical strength and elasticity of native pericardium, while providing the basic formative structure to support replacement by new endogenous tissue. This tissue is indicated for use in a variety of surgical applications, including duraplasty (as a substitute for human dura mater), and in abdominal, urological, opthalmological, and vascular surgery. The absorption process and reformation of endogenous tissue begins one to two days after implantation and continues for weeks, months, or years, depending on the size of the graft and the responsiveness of the graft site. Mentor Corporation has entered a strategic alliance with Tutogen Medical, Inc., to use the Tutoplast® technology to manufacture resorbable slings for urinary incontinence (Suspend™). [0007]
  • A variety of other uses of resorbable materials are described in the patent literature. See, for instance, U.S. Pat. No. 5,895,420 (Mirsch, II, et al., “Bioresorbable Heart Valve Support”), which, relates to bioprosthetic heart valve stents that are fashioned of resorbable materials. Such stents may be configured as sheaths or frames contoured to the shape of a valvular graft. The stents are eventually resorbed by the patient, leaving a functional “stentless” valve with improved hemodynamic characteristics compared to stented valve implants. [0008]
  • Various other resorbable materials have been suggested or proposed for use with vascular of non-vascular implants. For example, Goldberg et al., U.S. Pat. No. 5,085,629 discloses a biodegradable infusion stent for use in treating ureteral obstructions. Stack, et al., U.S. Pat. No. 5,306,286 discloses an absorbable stent for placement within a blood vessel during coronary angioplasty. Duran, U.S. Pat. No. 5,376,112 discloses an annuloplasty ring to be implanted into the heart to function together with the native heart valve. [0009]
  • In another aspect, U.S. Pat. No. 5,837,278 (Geistlich, et al., “Resorbable Collagen Membrane for Use in Guided Tissue Regeneration”), describes the use of a collagen-containing membrane in guided tissue regeneration. The patent provides a resorbable collagen membrane for use in guided tissue regeneration wherein one face of the membrane is fibrous thereby allowing cell growth thereon and the opposite face of the membrane is smooth, thereby inhibiting cell adhesion thereon. [0010]
  • Finally, see U.S. Pat. No. 5,413,798 (Scholl, et al.) which describes a process for treating bovine pericardial tissue to increase resistance to biological degradation by wet-chemical processing. The use of the tissue is exemplified in the form of an implant which, after three and six months post implantation, was well integrated so that it was no longer distinguishable from autochthonous dura (revitalized by fibrocytes and traversed by blood vessels in the marginal zones). The inner side of the implant is coated with the same cell type as the autologous dura. [0011]
  • On yet another topic, certain articles describe basic research directed to studying the effect of alkylating agents on materials such as collagen. See, for example, Sung, H. W., et al., J. Biomed. Mater. Res. 37:376-383 (1997) and Tu, R. et al., J. Biomed. Mater. Res., 28:677-684 (1994). To the best of Applicants' knowledge, however, no such reference suggests the manner in which such materials might be used in vivo, nor in turn, do they address the question of whether such materials can be tolerated, let alone resorbed and remodeled, by the body. [0012]
  • The present assignee is recognized as a leader in the development and manufacture of pericardium based materials. See, for instance, U.S. Pat. Nos. 5,752,965; 5,575,803; 5,549,628; 5,503,638; and 4,915,113 and International Application No. US98/25674, the disclosures of each of which are incorporated herein by reference. Generally, the pericardium materials are crosslinked, e.g., using glutaraldehyde, and hence are typically considered non-resorbable. Such materials have been used in a variety of applications, including as patches, suture and staple line buttress members, and pledgets. [0013]
  • SUMMARY OF THE INVENTION
  • The present invention provides a non-crosslinked, decellularized and purified mammalian tissue (e.g., bovine pericardium) having particular use as an implantable material in a manner that is both resorbable and remodelable. The material is prepared by alkylating the primary amine groups of natural tissue in a manner sufficient to reduce the antigenicity of the tissue, and in turn, to an extent that permits the treated tissue to be used in vivo and without crosslinking, thereby permitting it to be resorbable. [0014]
  • The material can be used, for instance, in surgical repair of soft tissue deficiencies, for a period of time, while the implant itself is gradually remodeled or absorbed by the host. In a related aspect, the invention provides a method of preparing such a material, as well as a method of using such a material for surgical repair. As used herein with respect to a material of the present invention, the word “resorb” and inflections thereof will refer to a material that, once implanted in vivo, is absorbed by the body over time and without undue deleterious effects on or within the body itself. The word “remodel” and inflections thereof, as used with regard to a material of the present invention, will refer to a resorbable material that is adapted, e.g., by virtue of its location and method of implantation within the body, to encourage and/or permit the body to replace some or all of the structure and/or function of the implant with newly formed natural tissue. While not intending to be bound by theory, at least in some embodiments of the present invention, remodeling appears to occur by gradual bodily processes in which substantial portions of the implant material are gradually resorbed, while an inherent fibrous network of the implant is retained at the site. The network, in turn, is used by the body as essentially scaffolding for the generation of new tissue or tissue components. [0015]
  • In a preferred embodiment, the invention provides a resorbable implantable material comprising a non-crosslinked, decellularized and purified mammalian tissue having most of its free amine groups alkylated. In a particularly preferred embodiment, the tissue is selected from the group consisting of pericardium, peritoneum, fascia lata, dura mater, dermis and small intestinal submucosa, and the material has been alkylated by an alkylating agent selected from the group consisting of 1,2-epoxy-R compounds where R is an alkyl group up to 6 carbon atoms. Such a material can be provided in any suitable form, e.g., as flat or textured sheets or strips, and can be adapted for use in a variety of surgical applications, including those selected from the group consisting of duraplasty, thoracic, abdominal, urological, opthalmological, cardiac, and vascular surgery. [0016]
  • DETAILED DESCRIPTION
  • A tissue of the present invention can be obtained from any suitable source including mammalian sources, e.g., in the form of collagenous connective tissue with three dimensional intertwined fibers. Such tissues generally include serous and fibro-serous membranes. In a particularly preferred embodiment, the tissue source is selected from bovine pericardium, peritoneum, fascia lata, dura mater, dermis, and small intestinal submucosa. In a further preferred embodiment, the tissue is bovine pericardium, and is treated using a method as described herein to provide the treated tissue with an optimal combination of biocompatability, thickness, and other physical and physiological properties. [0017]
  • Tissues of the present invention can be provided from dura mater, for instance, for use in neurosurgical applications. Collagenous connective tissue with three dimensional intertwined fibers, when treated in the manner described herein, retains the multidirectional and mechanical strength of native dura matter, while providing the basic formative structure to support replacement by new endogenous tissue. [0018]
  • While it is desirable to reduce or eliminate antigenic properties of xenografic or even allografic tissue-based material to be implanted into a body, if the body's absorption and/or remodeling of the material are desired, crosslinking cannot be performed. In order to specifically perform such modification of a collagen-based material, a monofunctional reagent is therefore used. The reagent is “monofunctional” in that it is adapted to react with, and therefore terminate or “cap” the available amine functionalities of tissue proteins, but will not further react with adjacent groups. An optimal reagent of this invention, therefore, is preferably a relatively small and structurally simple compound that, upon reaction with protein groups such as amines, will bind to those groups but will not otherwise alter the biological properties of the collagen matrix to an extent that renders the tissue unsuitable for its intended use. [0019]
  • In a particularly preferred embodiment, a tissue of the present invention is treated by a process that includes alkylating a major percentage of its available amine groups to an extent sufficient to permit the tissue to be implanted and used in vivo. Preferably a tissue is processed by alkylating its amines to an extent sufficient to react 80% or more, preferably 90% or more, and most preferably 95% or more of the amine groups originally present. The efficacy and extent of alkylation can be determined by a variety of means, as described herein, including the use of a ninhydrin-based assay (“amine index”) to determine a comparative level of amine groups, before and after treatment (see, e.g., Sung H-W, et al. Art Org., 21: 50-58; 1997. Sung, H-W, et al., J. Biomed. Mater. Res. 33: 177-186. 1996). Preferably the efficacy and extent of the alkylation process is further assessed by determining unreacted amounts in the batch incubation of the alkylating agent used. [0020]
  • Preferred alkylating agents can be used, for instance, at a pH of between about 9 and about 11, and at a concentration of between about 2% (v/v) and about 5% (v/v), by exposing the tissue to a solution containing the agent for at least 48 hours. [0021]
  • Preferred alkylating agents include small and reactive amine alkylating agents, such as formaldehyde, and 1,2-epoxy compounds. The epoxy agents offer an advantage over formaldehyde in that they tend to produce more stable adducts in their reactions with amines (Sung, H-W., et al., Biomater., 17: 2357-2365; 1996). 1,2-epoxy agents can react with a primary amine at alkaline pH to produce an extremely stable 2-hydroxy secondary amine. However, an aldehyde such as formaldehyde reacts with a primary amine to produce a marginally unstable, reversible double-bonded aldimine (Girardot, J-M. and Girardot, M-N., J. Heart Valve Dis., 5: 518-525; 1996). [0022]
  • Of the various monofunctional 1,2-epoxy agents, propylene oxide (“PO”) is particularly preferred since it possesses properties that render its inclusion into a material process simple, yet effective. Propylene oxide (epoxypropane) has been used for several years as a sterilant, mostly in a gaseous state, although at room temperature, it exists as a liquid (Hart, A. and Brown, W., Appl. Microbiol., 28: 1069-1070; 1975). Many years ago, PO was revealed to directly modify carboxylic, thiol, phenolic and amine groups of proteins under certain conditions (Fraenkal-Conrat, H., J. Biol. Chem., 154: 227-238; 1944). As has been demonstrated with other epoxides, propylene oxide reacts predominantly with amines at alkaline pH. Collagen swells at alkaline pH rendering it more accessible to be alkylated with a water-soluble agent such as propylene oxide. [0023]
  • Another preferred monofunctional epoxy reagent for use in the present invention is methyl glycidyl ether, as is produced by the Nagase Corp. of Osaka, Japan and sold under the product name Denacol® EX-131. This product has a low molecular weight, is water-soluble and was shown to be a more potent alkylator of porcine pericardium than formaldehyde (Sung, H-W., et al., J. Biomed. Mater. Res., 35: 147-155; 1997). [0024]
  • In addition to the “amine index”, another test may be used to confirm tissue modification by an amine alkylating agent. The denaturation (shrink) temperature (T[0025] d) is often used to verify the crosslinking of collagen by an agent such as glutaraldehyde. It is typically observed that upon chemical crosslinking, the Td increases significantly, apparently due to increased stabilization of the hydrogen bonds present in the collagen. In contrast, upon alkylation with a monofunctional agent such as propylene oxide, the Td decreases significantly. This phenomenon is believed to occur due to branching of the collagen polymer by the action of the alkylating agent and the subsequent alteration of the collagen matrix (Tu, R., et al., J. Biomed. Mater. Res., 28: 677-684; 1994).
  • In a preferred embodiment, a tissue of the present invention is also treated with a base such as sodium hydroxide (NaOH), in order to further lesson the already minimal possibility of Bovine Spongiform Encephalopathy (BSE) transmission. Histological analyses of NaOH-treated tissue (pericardium, for example) reveals virtually complete decellularization due to this treatment. Since the cellular component of tissue is known to contain the vast majority of the antigen load (Courtman, D. W., et al., J. Biomed. Mater. Res., 28: 655-666; 1994), decellularization treatment with NaOH can complement the use of an alkylating agent in reducing antigenicity. [0026]
  • A tissue of the present invention can be used to fabricate a prosthetic article having any suitable shape or configuration, and in any suitable dimensions for its intended use. For instance, the tissue can be provided and packaged in a flat configuration (e.g., sheet or tape-like), with either or both major surfaces thereof being optimally textured or modified (e.g., by the covalent attachment, entrapment, and/or adsorption of biologically active factors, lubricious agents, antimicrobial agents and the like). [0027]
  • In a preferred embodiment, a process of the present invention includes the steps of: [0028]
  • a) obtaining pericardium from a suitable (e.g., USDA-approved) source, [0029]
  • b) cleaning the tissue and optionally, and preferably, treating the tissue, e.g., in order to decellularize it and/or to reduce/eliminate potential BSE infectivity, [0030]
  • c) alkylating the tissue (e.g., hydroxypropylation using propylene oxide) to cap a major percentage of available (e.g., potentially reactive) amine groups, and optionally, [0031]
  • d) final processing, including one or more of the following steps: washing, drying, sterilizing and packaging the tissue. [0032]
  • Natural tissues suitable for use in the process of this invention preferably meet stringent specifications during donor screening and laboratory testing to reduce the risk of transmitting infectious disease. Processing of tissue involves a strict, quality-controlled procedure, which involves thorough cleaning, processing, dehydration and preservation. The process leaves no deleterious residue and minimizes antigenic potential. Sterilization is preferably achieved with the use of gamma or electron beam radiation (typically 2.5 Mrad) or ethylene oxide gas. [0033]
  • A treated tissue of the present invention is indicated for implantation with a spectrum of indications. Collagenous connective tissue of this sort, having multidirectional fibers, is able to retain a substantial amount of the mechanical strength and elasticity of native pericardium, while providing the basic formative structure in situ to support replacement by new endogenous tissue. This tissue is indicated for use in a variety of surgical applications, including duraplasty (as a substitute for human dura mater), and in thoracic, abdominal, urological, opthalmological, cardiac and vascular surgery. [0034]
  • Implantation should be avoided into areas with active or latent infection or signs of tissue necrosis, as well as into areas with compromised circulation or in any disorder that would create an unacceptable risk of post-operative complications. [0035]
  • The tissue can be packaged using conventional means, such that the tissue and package contents remain sterile and non-pyrogenic as long as the package is not opened and/or damaged. The graft must be used before the expiration date. Those skilled in the appropriate art will appreciate the manner in which appropriate placement and fixation of the tissue in situ can be critical factors in avoiding potentially adverse effects on the graft service life. A tissue of this invention can be prepared and packaged in various sizes (e.g., thickness, length and width). The dimensions of tissue used should correspond to the size of the respective defect. [0036]
  • Once implanted, the absorption process and reformation of endogenous tissue begins one to two days after implantation and continues for weeks, months, or years, depending on the size of the graft and the responsiveness of the graft site. It is recommended that, if packaged in a dry or dehydrated condition, the tissue be rehydrated prior to use for about 2 to about 30 minutes, depending on the consistency desired, using aseptic/sterile technique. The surgeon should also monitor the effect of rehydration by visual inspection, both in the course of rehydration and while cutting and shaping the graft. Implantation should be performed in such a way that the free edges of the implant do not extend into areas where the possibility of adhesion may present a problem. [0037]
  • Absorbable or nonabsorbable suture material, glue, etc. can be used to fix the tissue in place. For a continuous suture, absorbable suture material and round atraumatic needles are recommended, while suture gauge depends on the surgical indication. The suture should be located two to three millimeters from the edge of the graft. Better results are obtained by doubling the section at suture sites that are under moderate to high stress. [0038]
  • Tissues of the present invention provide a variety of features and advantages, including the fact that they are immediately available for surgery and can save valuable operating room time. Moreover, there is no secondary surgery site and less stress for the patient; which can result in less time under anesthesia, no donor site pain or morbidity, and less cost. Since the tissues can be made available in a wide range of sizes, the surgeon can choose the size needed, leading to minimal waste. As with all biological products, it is not possible to provide an absolute guarantee of freedom from contaminating infectious diseases such as hepatitis, Creutzfeld-Jakob Disease (CJD) or Bovine Spongiform Encephalopathy (BSE). Processing treatments, such as the use of NaOH in the cases of CJD and BSE, have shown to be capable of reducing the risk of any transmission, and are particularly useful in combination with strict donor screening and laboratory testing. Treated tissues of the present invention can be stored in a clean, dry environment and at controlled temperatures between 4° C. and 30° C. (59° to 86° F.). [0039]
  • TEST PROCEDURES
  • Collagenase Assay [0040]
  • The enzyme class referred to as collagenase has been used for several years in studying its effects on collagenous biomaterials. Bacterial collagenase, e.g., from [0041] Clostridium histolyticum, can be used as an accurate predictor of the propensity and rate of resorption of a material by a mammalian host (Yannas, I. V., et al., J. Biomed. Mater. Res., 9: 623-628; 1975). Since modification of collagen by a crosslinking agent results in greatly diminished susceptibility to the action of collagenase, it is important that such modification not be performed on tissue to be resorbed. The mechanism by which crosslinking hinders the activity of collagenase is not completely understood. Surprisingly, applicants have found that bacterial collagenase is in fact able to degrade treated (alkylated) tissues of the present invention. Thus, tissue alkylated by an agent such as PO possesses pertinent and functional properties, and the collagenase assay remains a useful tool for confirming the utility of thus-treated tissue.
  • The collagenase assay is a ninhydrin-based assay for the indication of soluble collagen peptides produced by the action of the collagenase enzyme, and can be performed as follows: [0042]
  • 1. Weigh out tissue in the range of 25-30 milligrams. [0043]
  • 2. Add 3.0 milliliters of collagenase solution [0.01 mg/ml Collagenase enzyme (Sigma, type 1A) in 50 mM N-tris[hydroxymethyl]methyl-2 aminoethane sulfonic acid (“TES”) buffer with 25 mM calcium chloride, pH 7.4-7.5]. [0044]
  • 3. Incubate at 37° C. for 24 to 96 hours. [0045]
  • 4. At allotted timepoints, incubate 100 μl of collagenase solution and 1.0 ml ninhydrin solution [one part 4% (w/v) ninhydrin in ethylene glycol monoethyl ether to one part 200 mM citric acid, 0.16% (w/v) stannous chloride, pH 5.0] at 95-100° C. for 30 minutes. [0046]
  • 5. Cool tubes at room temperature. [0047]
  • 6. Add 250 μl of collagenase sample to 1.0 ml 50% isopropanol. [0048]
  • 7. Vortex and read absorbance at 570 nm. [0049]
  • 8. The absorbance at 570 nm is divided by the weight of the piece of tissue to give the OD/mg. The OD/mg is the value for the amount of collagen peptides that has been degraded by the action of the collagenase enzyme. [0050]
  • The results of the collagenase assay are determined by comparing the sample with both positive (untreated) and negative (glutaraldehyde crosslinked) control samples. [0051]
  • Amine Index [0052]
  • The amine index can be defined as the percentage of initially available amines that have been modified (and thereby rendered substantially nonreactive in vivo) by reaction with amine reagents. Such modification will render the amine unable to produce “Ruhemann's purple” when introduced to ninhydrin, and the relevant assay can be performed as follows: [0053]
  • 1. 200 μl of DI water were added to 25-30 milligrams of tissue. [0054]
  • 2. Add one milliliter of ninhydrin solution to each tube. [0055]
  • 3. Incubate tubes at 95-100° C. for 30-35 minutes. [0056]
  • 4. Cool tubes at room temperature. [0057]
  • 5. Add 250 μl of sample to one milliliter of 50% isopropanol solution. [0058]
  • 6. Vortex and read absorbance at 570 nm. [0059]
  • 7. The amine index is calculated. [0060]
  • In order to calculate the percentage of original amines modified, the following formula is used: [0061] Amine Index ( % ) = [ * Control ( OD / mg ) - Sample ( OD / mg ) ] Control ( OD / mg ) × 100
    Figure US20040107006A1-20040603-M00001
  • The OD/mg is found by dividing the OD @ 570 by the weight of the piece of tissue. * The control is unmodified tissue. [0062]
  • Assay for Quantitation of Unreacted Alkylating Agent [0063]
  • The purpose of this assay is to confirm that although 100% amine alkylation is typically not attained, it is not due to the lack of adequate alkylating agent. In essence, this assay is used to confirm that detectable levels of alkylating agent remain in the incubation solution upon exhaustive exposure to the tissue. Upon exposure of tissue to an alkylating agent, the agent solution can be sampled in order to quantitate the percentage remaining. This test is in part performed for the purpose of assessing the efficiency of alkylation. Quantitation is assessed using a standard curve. [0064]
  • 1. 10 mM Glycine solution is prepared by adding 0.0375 grams of glycine to 50 milliliters of 0.2 M carbonate (Na[0065] +2) buffer.
  • 2. Propylene oxide (PO) standards are prepared (e.g., ranging from 0.5% PO to 5% PO). The standards are prepared by adding the correct amount of PO to the carbonate buffer for a total of five milliliters. [0066]
  • 3. Add 1 milliliter of the glycine solution to labeled test tubes. [0067]
  • 4. Add 1 milliliter of each PO standard to the labeled test tube. [0068]
  • 5. Vortex to mix and allow to react for 24 hours at room temperature. [0069]
  • 6. After 24 hours, 50 μl of each standard was added to one milliliter of ninhydrin solution. [0070]
  • 7. Incubate tubes at 95-100° C. for 30 minutes. [0071]
  • 8. Cool tubes at room temperature. [0072]
  • 9. Add 250 μl of standard to one milliliter of 50% isopropanol solution. [0073]
  • 10. Vortex and read absorbance at 570 nm. [0074]
  • The samples containing unknown propylene oxide concentrations are assessed using the method above. Once the propylene oxide standard curve is plotted, the samples containing unknown propylene oxide concentrations can be estimated using the standard curve. [0075]
  • Moisture Content [0076]
  • Moisture content was analyzed on a Mettler-Toledo HG53 Halogen Moisture Analyzer. A temperature setting of 200° C. was used. Results are recorded in % moisture content. [0077]
  • Denaturation (Shrink) Temperature [0078]
  • Denaturation temperature is the temperature at which the collagen denatures. The test was performed on the ChemDyne MC1000 tensile testing system. The denaturation temperature was measured using a 30 gram preload in a bath of water at steadily increasing temperature. Results are expressed in ° C. [0079]
  • The invention will be further described with reference to the following non-limiting Examples. It will be apparent to those skilled in the art that many changes can be made in the embodiments described without departing from the scope of the present invention. Thus the scope of the present invention should not be limited to the embodiments described in this application, but only by embodiments described by the language of the claims and the equivalents of those embodiments.[0080]
  • EXAMPLE 1
  • Bovine pericardial sacs were harvested from USDA inspected healthy cows, minimum age of 12 months. Fresh pericardium was obtained and sent through a series of rinses, followed by a final ice cold water rinse. The tissue was cleaned of extraneous tissue, and used fresh or stored at −20° C. The following general procedures were used to prepare treated tissue according to the present invention. [0081]
  • All test procedures are performed at 20-25° C. [0082]
  • NaOH & Neutralization [0083]
  • 1. Weigh out 40-45 grams of bovine pericardium. [0084]
  • 2. Place pericardium into one liter of 1.0 M NaOH (40 grams of NaOH in one liter of DI water) for 60-65 minutes. Take a sample for pH measurement at the end of soak. [0085]
  • 3. Decant NaOH; gently squeeze tissue and place in two liters of filtered DI water for 15-20 minutes. [0086]
  • 4. Decant DI water and place tissue in two liters of citrate buffer (28 grams of sodium citrate and 2.0 grams of citric acid in two liters of DI water) for 60-65 minutes. Take a sample for pH measurement at the end of soak. [0087]
  • 5. Decant citrate buffer, gently squeeze tissue and place tissue in another two liters of DI water for 30-35 minutes. [0088]
  • Alkylation of Tissue [0089]
  • 1. Prepare 5% Propylene Oxide solution (50 milliliters of propylene oxide in 950 milliliters of 0.2 M carbonate buffer, pH 10.5-10.6). [0090]
  • 2. Place NaOH-treated tissue in propylene oxide solution. [0091]
  • 3. Mix on platform shaker for 72-96 hours. [0092]
  • 4. Remove tissue from solution and place in 1.5 liters of DI water for 24 hours. [0093]
  • After hydroxypropylation of tissue, the amine index and the quantitation of unreacted alkylating agent assays are performed to verify sufficient alkylation and PO. The tissue was transferred onto wire mesh racks and dried in a Virtis Genesis vacuum dryer at 115 mtorr. [0094]
  • RESULTS Table 1 Collagenase Activity
  • The table below provides the results of a collagenase assay when resorbable tissue prepared in the manner described herein was incubated in 0.01 mg/ml collagenase for 24-96 hours. [0095] TABLE 1 Tissue 24 hr OD/mg 48 hr OD/mg 72 hr OD/mg 96 hr OD/mg Untreated 0.319 0.423 0.459 0.481 NaOH 0.502 0.689 0.784 0.874 NaOH/PO 0.674 0.684 0.822 0.973
  • OD/mg is the relative value for the amount of collagen that has been degraded by the action of the collagenase enzyme. It can be seen that each of the tissues, including the alkylated tissue of this invention, are susceptible to collagenase digestion, indicating the likelihood that they would be resorbed within the body. [0096] TABLE 2 pH Dependence The following table provides the amine index results of NaOH/PO- treated tissue when incubated in a 5% PO solution at two different pHs. Tissue Amine Index @ pH 9.5 Amine Index @ pH 10.5 NaOH/PO 84.76% 96.29%
  • It can be seen that, under the experimental circumstances involved, the extent of alkylation could be increased at higher pH. [0097] TABLE 3 Time Dependence The following table provides the amine index results of NaOH/PO- treated tissue when incubated in a 5% PO solution for a period of time at a pH of 10.5. Tissue 72 hr PO incubation 96 hr PO incubation NaOH/PO 93.95% 96.29%
  • It can be seen that there is a slight increase in alkylation, even in the period from 72 to 96 hour incubation. [0098] TABLE 4 Assay to Quantitate Unreacted Alkylating Agent The table below is an example of a standard curve from the assay for unreacted alkylating agent. 0% 0.5% 1% 2% 3% 4% 5% OD @ 570 0.919 0.707 0.556 0.363 0.274 0.241 0.088 OD @ 570 Unreacted 0.7734 Alkylating agent
  • When the data above is plotted it provides a standard curve, and in a typical preparation, it can be estimated that under the experimental conditions of this example, between 0.4 and 0.5% propylene oxide remains unreacted in the alkylation solution. [0099] TABLE 5 Moisture Content The table below shows how the moisture content tends to increase as the tissue goes through the alkylation process (between 72-96 hours). Tissue Moisture Content (%) Untreated 78.35 NaOH 87.33 NaOH/PO 89.28
  • [0100] TABLE 6 Denaturation Temperature The table below indicates the manner in which the denaturation (shrink) temperature tends to decrease as the tissue goes through the alkylation process. Tissue Denaturation temperature Untreated 65.1° C. NaOH 62.4° C. NaOH/PO 49.2° C.
  • EXAMPLE 2 In Vivo Biocompatibility and Biostability Study of PO-Capped Bovine Pericardium
  • In this study, propylene oxide (PO) capped, non-crosslinked bovine pericardium was compared with glutaraldehyde (GA) crosslinked bovine pericardium in a subcutaneous animal model, in terms of inflammation, changes in physical property, and remodeling of implant matrix with the host tissue. [0101]
  • Preparation of PO Treated Tissue [0102]
  • Patches (approximately 4 cm×6 cm) of fresh bovine pericardium were first treated in 1N NaOH for one hour, followed by immersion 2-3 times in 4L of 50 mM citrate buffer for 1 hour. The NaOH treated tissue was then put in large test tubes containing 100 ml of 0.2 M NaHCO[0103] 3 buffer at pH 10.5 and 2% propylene oxide. The tubes were gently shaken on an automatic rocker for 48 hours at room temperature. The tissue was thoroughly washed with saline to a pH level of 6.5-7.5, and then stored in 70% ethanol.
  • Preparation of GA Crosslinked Tissue [0104]
  • Glutaraldehyde (GA) crosslinked bovine pericardium patches are commercially available under the tradename “Peri-Guard”, including Supple Peri-Guard™, and were obtained from Bio-Vascular, Inc., St. Paul, Minn. [0105]
  • Sterilization [0106]
  • The wet tissue patches were cut into a sample size of 1 cm×2 cm. The samples were laid flat on a plastic wrap (four each) and enclosed by folding the plastic wrap around. The wrapped samples were placed inside plastic/aluminum foil pouches that were subsequently purged with Argon gas and heat-sealed. The pouches were sent for sterilization by electron beam radiation at 25±2.5 KGy. [0107]
  • Implantation [0108]
  • The animals were 3 month old Fisher 344 male rats. Each animal received two different material implants. Upon the surgical procedures, the animals were anesthetized with pentobarbital (5 mg/100 g), and the upper backs were shaved and washed with a butadiene solution. A 2 cm incision was made over the midline on the back of the animal. The subcutaneous tissue plains were dissected laterally to form a pouch on the left and right sides of the back. One sample was inserted and spread flat in each pouch. Wounds were closed with surgical sutures and washed with butadiene. The animals were returned to their cages after recovering from anesthesia. [0109]
  • Explantation [0110]
  • At 4 and 12 weeks post-implantation, animals were sacrificed by carbon dioxide inhalation. The samples were retrieved together with the surrounding adherent tissue. The retrieved samples were cut in 3 pieces. One piece was stored in saline with 0.3% sodium azide and used for suture retention test, the second one fixed in Bouin fixatives and sent for embedding, sectioning and hematoxylin and eosin (“H&E”) staining, and the third piece stored frozen and used for enzymatic digestion assays. [0111]
  • Suture Retention Measurement [0112]
  • A suture retention test that determines the force necessary to pull a suture loop from the prosthesis was performed on the ChemDyne MC1000 (Columbia Labs, Inc.) tensile testing system. A 5-0 Prolene suture was looped through the tissue with a 2 mm bite below the edge of the tissue. The suture loop was pulled at a rate of 100 mm/min with sampling rate of 20 Hz. [0113]
  • Enymatic Digestion Assays [0114]
  • The tissue samples were immersed in 1.0 ml of 40 U/ml collagenase (Worthington, Biochem Corp.) and 1.0 ml of 0.05% trypsin/EDTA solution, respectively. The samples were incubated for 12 hours at 37° C. and scored visually for tissue integrity. [0115]
  • Results
  • Suture Retention [0116]
  • While GA crosslinked bovine pericardium substantially maintained its suture retention property throughout the implantation period (up to 12 weeks after E-beam sterilization), there were substantial changes in the PO capped tissue following E-beam sterilization as well as implantation (Table 7). It appears that E-beam radiation reduced the suture retention of PO capped tissue by about 60%. The suture retention was further reduced during the implantation period. However, it is interesting that the suture retention of PO capped tissue appeared to increase with time after reaching the lowest level at 4 weeks post-implantation. [0117] TABLE 7 Suture Retention Force (g) of Tissue Samples Before and After E-Beam Sterilization and Implantation in Rats Tissue Materials GA Crosslinked (SPG) PO Capped Prior to E-Beam & 1180 ± 50  (n = 4) 802 ± 212 (n = 4) Implantation Post E-Beam, Prior to Not Tested 300 ± 19  (n = 4) Implantation  4 Weeks Post Implantation 914 ± 173 (n = 4) 82 ± 29  (n = 4) 12 Weeks Post Implantation 1039 ± 145 (n = 4) 157 ± 39  (n = 4)
  • Enzymatic Digestion [0118]
  • GA crosslinking rendered bovine pericardium resistant to collagenase and/or trypsin before and after implantation (up to 12 weeks). However, the PO capped bovine pericardium was readily digested by collagenase as well as trypsin prior to implantation. Since bovine pericardium is largely made of collagen that in its natural state (i.e., non-crosslinked) can be digested by collagenase but not trypsin, it is interesting that the tissue became susceptible to trypsin after PO capping. Following implantation, the PO capped samples were totally digestible by trypsin at 4 weeks, but partially at 12 weeks. It is possible that new collagen formed in the samples at later stages of implantation. [0119]
  • Histological Evaluation [0120]
  • The histological slides (H&E stain) were evaluated under an optical microscope and scored under a scale of 1 to 4 (Table 7). At 4 weeks post-implantation, the GA crosslinked samples induced a slight to moderate level of inflammatory response as characterized by considerable amounts of polymorphonuclear leukocytes (PMN's), macrophages, and foreign body giant cells, as well as lymphocytes, found mainly at the outer surfaces of the implant. In comparison, very mild or no reaction was found for the PO capped samples that looked clean with very few inflammatory cells present. Fibrous encapsulation was evident around the GA crosslinked tissue implants, but almost not detectable in PO capped samples. Collagen fiber structure in the GA crosslinked tissue matrix was unchanged, while the tissue matrix of PO capped implants appeared delaminated and loose. [0121]
  • At 12 weeks post-implantation, while the inflammatory response to the GA crosslinked tissue was similar to that at 4 weeks with little change in the physical integrity, there were marked changes in the PO treated samples. There were more cellular infiltrates (especially fibroblasts) around, as well as within, the PO treated tissue. The PO capped tissue matrix became uniform and anisotropic with no wavy fibrous structure as observed in regular bovine pericardium. In some regions under a thin fibrous capsule, the tissue matrix resembled the characteristics of developing granulation tissue with fibroblasts, neo-collagen and macrophages. [0122] TABLE 7 Microscopic Evaluation (Scale of 1 to 4) of Explants at 4 and 12 Weeks GA GA PO PO Crosslinked Crosslinked Capped Capped Parameters (4 Weeks) (12 Weeks) (4 Weeks) (12 Weeks) Poly- 2 2 1 1 morphoneuclear (PMNs) Lymphocytes 2 2 1 1 Plasma Cells 0 0 0 0 Macrophages 1 2 0 1 Giant Cells 2 2 0 1 Necrosis 0 0 0 0 Fibroplasia 0 0 0 0 Fibrosis 2 3 1 2 Fatty Infiltrate 0 0 0 0 Fibroblast 0 0 1 2 Proliferation
  • In conclusion, compared with the GA crosslinked bovine pericardium, the PO capped, non-crosslinked bovine pericardium induced less inflammation as indicated by fewer inflammatory cells (such as PMNs and macrophages) present at 4 and 12 weeks post-implantation. While the GA crosslinked tissue maintained most of its physical and structural integrity throughout the implantation period, the PO capped tissue appeared to undergo significant changes during implantation. Following implantation, the PO capped tissue was partially degraded within the first few weeks resulting in decreases in suture retention. Interestingly, however, instead of being totally adsorbed in the body the material appeared to be remodeled over time with new host tissue and became stronger with increasing suture retention. New collagen formation probably occurred in the remodeling process as indicated by fibroblast proliferation and increased resistance of the explants to trypsin digestion at 12 weeks. Histological examination revealed that at later stages (e.g. 12 weeks) of implantation the matrix of PO capped bovine pericardium began to resemble the granulation tissue, which is the specialized type of tissue that is indicative of a normal healing process. [0123]

Claims (14)

What is claimed is:
1. A resorbable, remodelable implant material comprising a sterile, non-crosslinked, decellularized and purified mammalian tissue having a major percentage of its available amine groups alkylated.
2. A material according to claim 1 wherein the tissue is selected from the group consisting of serous and fibro-serous membranes.
3. A material according to claim 2 wherein the tissue is selected from the group consisting of pericardium, peritoneum, fascia lata, dura mater, dermis and small intestinal submucosa.
4. A material according to claim 3 wherein the tissue comprises bovine pericardium.
5. A material according to claim 1 wherein the material has been alkylated by an alkylating agent selected from the group consisting of 1,2-epoxy-R compounds where R is an alkyl group up to 6 carbon atoms.
6. A material according to claim 5 wherein the alkylating agent is propylene oxide.
7. A material according to claim 1 wherein the alkylating agent is methyl glycidyl ether.
8. A material according to claim 1 wherein the material is provided in the form of flat or textured sheets or strips.
9. A material according to claim 1 wherein the material is adapted for use in a surgical application selected from the group consisting of duraplasty, thoracic, abdominal, urological, opthalmological, cardiac, and vascular surgery.
10. A process of preparing a resorbable, remodelable implant material according to claim 1, the method comprising the step of treating a biological tissue with an alkylating agent under conditions suitable to alkylate a major percentage of available amine groups in the tissue, and sterilizing the treated tissue for use in vivo.
11. A process according to claim 10 wherein the cleaned tissue is treated with a base prior to the alkylating step.
12. A process according to claim 10 wherein the alkylating agent is used at a pH of between about 9 and about 11.
13. A process according to claim 10 wherein the concentration of alkylating agent is between about 2% (v/v) and about 5% (v/v).
14. A process according to claim 10 wherein the tissue is exposed to the alkylating agent for at least 48 hours.
US10/722,034 1999-09-15 2003-11-24 Resorbable implant materials Abandoned US20040107006A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US09/396,279 US6312474B1 (en) 1999-09-15 1999-09-15 Resorbable implant materials
PCT/US2000/025234 WO2001019423A1 (en) 1999-09-15 2000-09-14 Resorbable implant materials
US10/099,425 US6652594B2 (en) 1999-09-15 2002-03-14 Resorbable implant materials
US10/722,034 US20040107006A1 (en) 1999-09-15 2003-11-24 Resorbable implant materials

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/722,034 US20040107006A1 (en) 1999-09-15 2003-11-24 Resorbable implant materials

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/099,425 Continuation US6652594B2 (en) 1999-09-15 2002-03-14 Resorbable implant materials

Publications (1)

Publication Number Publication Date
US20040107006A1 true US20040107006A1 (en) 2004-06-03

Family

ID=23566590

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/396,279 Expired - Lifetime US6312474B1 (en) 1999-09-15 1999-09-15 Resorbable implant materials
US10/099,425 Expired - Lifetime US6652594B2 (en) 1999-09-15 2002-03-14 Resorbable implant materials
US10/722,034 Abandoned US20040107006A1 (en) 1999-09-15 2003-11-24 Resorbable implant materials

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/396,279 Expired - Lifetime US6312474B1 (en) 1999-09-15 1999-09-15 Resorbable implant materials
US10/099,425 Expired - Lifetime US6652594B2 (en) 1999-09-15 2002-03-14 Resorbable implant materials

Country Status (9)

Country Link
US (3) US6312474B1 (en)
EP (1) EP1212105B1 (en)
JP (2) JP5362937B2 (en)
AT (1) AT265241T (en)
AU (1) AU772182B2 (en)
CA (1) CA2384961C (en)
DE (1) DE60010287T2 (en)
ES (1) ES2220530T3 (en)
WO (1) WO2001019423A1 (en)

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245965A1 (en) * 2002-06-17 2005-11-03 Orban Iii Joseph P Annular support structures
US20060085030A1 (en) * 2004-10-15 2006-04-20 Bettuchi Michael J Seal element for anastomosis
US20060085034A1 (en) * 2004-10-18 2006-04-20 Bettuchi Michael J Support structures and methods of using the same
US20060135992A1 (en) * 2004-10-18 2006-06-22 Bettuchi Michael J Annular adhesive structure
US20070203509A1 (en) * 2006-02-28 2007-08-30 Bettuchi Michael J Hub for positioning annular structure on a surgical device
US20070203510A1 (en) * 2006-02-28 2007-08-30 Bettuchi Michael J Annular disk for reduction of anastomotic tension and methods of using the same
US20080140115A1 (en) * 2004-08-17 2008-06-12 Stopek Joshua B Stapling Support Structures
US20080308608A1 (en) * 2007-06-18 2008-12-18 Prommersberger Megan L Interlocking buttress material retention system
US20080314960A1 (en) * 2007-06-22 2008-12-25 Stanislaw Marczyk Detachable buttress material retention systems for use with a surgical stapling device
US20090001122A1 (en) * 2007-06-27 2009-01-01 Megan Prommersberger Buttress and surgical stapling apparatus
US20090054995A1 (en) * 2007-07-24 2009-02-26 Aesculap Ag, A Corporation Of Germany Planar implant
US20090134200A1 (en) * 2007-03-06 2009-05-28 Danyel Tarinelli Surgical stapling apparatus
US20090218384A1 (en) * 2007-06-18 2009-09-03 Ernie Aranyi Structure for attachment of buttress material to anvils and cartridges of surgical staplers
US20100012704A1 (en) * 2007-03-06 2010-01-21 Danyel Tarinelli Racenet Surgical Stapling Apparatus
US20100012703A1 (en) * 2005-05-05 2010-01-21 Allison Calabrese Surgical Gasket
US20100065606A1 (en) * 2006-10-26 2010-03-18 Stopek Megan L Methods of Using Shape Memory Alloys for Buttress Attachment
US20100082114A1 (en) * 2008-04-29 2010-04-01 Peter Gingras Tissue repair implant
US20100249805A1 (en) * 2009-03-31 2010-09-30 Lee Olson Crimp And Release Of Suture Holding Buttress Material
US20100243708A1 (en) * 2009-03-31 2010-09-30 Ernie Aranyi Surgical stapling apparatus
US20100243707A1 (en) * 2009-03-31 2010-09-30 Lee Olson Surgical stapling apparatus
US7845536B2 (en) 2004-10-18 2010-12-07 Tyco Healthcare Group Lp Annular adhesive structure
US7967179B2 (en) 2009-03-31 2011-06-28 Tyco Healthcare Group Lp Center cinch and release of buttress material
US8016177B2 (en) 2007-05-25 2011-09-13 Tyco Healthcare Group Lp Staple buttress retention system
US8157151B2 (en) 2009-10-15 2012-04-17 Tyco Healthcare Group Lp Staple line reinforcement for anvil and cartridge
US8167895B2 (en) 2005-03-15 2012-05-01 Tyco Healthcare Group Lp Anastomosis composite gasket
US8348126B2 (en) 2009-03-31 2013-01-08 Covidien Lp Crimp and release of suture holding buttress material
US8348130B2 (en) 2010-12-10 2013-01-08 Covidien Lp Surgical apparatus including surgical buttress
US8365972B2 (en) 2009-03-31 2013-02-05 Covidien Lp Surgical stapling apparatus
US8479968B2 (en) 2011-03-10 2013-07-09 Covidien Lp Surgical instrument buttress attachment
US8668129B2 (en) 2008-12-16 2014-03-11 Covidien Lp Surgical apparatus including surgical buttress
US8789737B2 (en) 2011-04-27 2014-07-29 Covidien Lp Circular stapler and staple line reinforcement material
US8820606B2 (en) 2012-02-24 2014-09-02 Covidien Lp Buttress retention system for linear endostaplers
US8870050B2 (en) 2011-11-04 2014-10-28 Covidien Lp Surgical stapling apparatus including releasable buttress
US8967448B2 (en) 2011-12-14 2015-03-03 Covidien Lp Surgical stapling apparatus including buttress attachment via tabs
US9010608B2 (en) 2011-12-14 2015-04-21 Covidien Lp Releasable buttress retention on a surgical stapler
US9010609B2 (en) 2012-01-26 2015-04-21 Covidien Lp Circular stapler including buttress
US9010612B2 (en) 2012-01-26 2015-04-21 Covidien Lp Buttress support design for EEA anvil
US9084602B2 (en) 2011-01-26 2015-07-21 Covidien Lp Buttress film with hemostatic action for surgical stapling apparatus
US9113885B2 (en) 2011-12-14 2015-08-25 Covidien Lp Buttress assembly for use with surgical stapling device
US9161753B2 (en) 2012-10-10 2015-10-20 Covidien Lp Buttress fixation for a circular stapler
US9192383B2 (en) 2013-02-04 2015-11-24 Covidien Lp Circular stapling device including buttress material
US9192384B2 (en) 2012-11-09 2015-11-24 Covidien Lp Recessed groove for better suture retention
US9204881B2 (en) 2013-01-11 2015-12-08 Covidien Lp Buttress retainer for EEA anvil
US9237892B2 (en) 2011-12-14 2016-01-19 Covidien Lp Buttress attachment to the cartridge surface
US9295466B2 (en) 2012-11-30 2016-03-29 Covidien Lp Surgical apparatus including surgical buttress
US9326773B2 (en) 2012-01-26 2016-05-03 Covidien Lp Surgical device including buttress material
US9351731B2 (en) 2011-12-14 2016-05-31 Covidien Lp Surgical stapling apparatus including releasable surgical buttress
US9351732B2 (en) 2011-12-14 2016-05-31 Covidien Lp Buttress attachment to degradable polymer zones
US9364229B2 (en) 2005-03-15 2016-06-14 Covidien Lp Circular anastomosis structures
US9402627B2 (en) 2012-12-13 2016-08-02 Covidien Lp Folded buttress for use with a surgical apparatus
US9414839B2 (en) 2013-02-04 2016-08-16 Covidien Lp Buttress attachment for circular stapling device
US9433420B2 (en) 2013-01-23 2016-09-06 Covidien Lp Surgical apparatus including surgical buttress
US9486215B2 (en) 2009-03-31 2016-11-08 Covidien Lp Surgical stapling apparatus
US9504470B2 (en) 2013-02-25 2016-11-29 Covidien Lp Circular stapling device with buttress
US9522002B2 (en) 2012-12-13 2016-12-20 Covidien Lp Surgical instrument with pressure distribution device
US9572576B2 (en) 2012-07-18 2017-02-21 Covidien Lp Surgical apparatus including surgical buttress
US9610080B2 (en) 2009-10-15 2017-04-04 Covidien Lp Staple line reinforcement for anvil and cartridge
US9629626B2 (en) 2006-02-02 2017-04-25 Covidien Lp Mechanically tuned buttress material to assist with proper formation of surgical element in diseased tissue
US9655620B2 (en) 2013-10-28 2017-05-23 Covidien Lp Circular surgical stapling device including buttress material
US9675351B2 (en) 2011-10-26 2017-06-13 Covidien Lp Buttress release from surgical stapler by knife pushing
US9681936B2 (en) 2012-11-30 2017-06-20 Covidien Lp Multi-layer porous film material
US9693772B2 (en) 2009-10-15 2017-07-04 Covidien Lp Staple line reinforcement for anvil and cartridge
US9782173B2 (en) 2013-03-07 2017-10-10 Covidien Lp Circular stapling device including buttress release mechanism
US9844378B2 (en) 2014-04-29 2017-12-19 Covidien Lp Surgical stapling apparatus and methods of adhering a surgical buttress thereto
US9931116B2 (en) 2012-02-10 2018-04-03 Covidien Lp Buttress composition
US10293553B2 (en) 2009-10-15 2019-05-21 Covidien Lp Buttress brachytherapy and integrated staple line markers for margin identification
US10368868B2 (en) 2017-03-09 2019-08-06 Covidien Lp Structure for attaching buttress material to anvil and cartridge of surgical stapling instrument
US10420556B2 (en) 2012-11-09 2019-09-24 Covidien Lp Surgical stapling apparatus including buttress attachment

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066325A (en) * 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US8603511B2 (en) 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
CA2335152C (en) * 1998-05-14 2008-11-18 The Cleveland Clinic Foundation Processing of implantable animal tissues for dry storage
US7452371B2 (en) * 1999-06-02 2008-11-18 Cook Incorporated Implantable vascular device
US7063726B2 (en) * 1998-06-30 2006-06-20 Lifenet Plasticized bone grafts and methods of making and using same
US6293970B1 (en) * 1998-06-30 2001-09-25 Lifenet Plasticized bone and soft tissue grafts and methods of making and using same
US6214054B1 (en) 1998-09-21 2001-04-10 Edwards Lifesciences Corporation Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby
US7892229B2 (en) * 2003-01-18 2011-02-22 Tsunami Medtech, Llc Medical instruments and techniques for treating pulmonary disorders
US8016823B2 (en) 2003-01-18 2011-09-13 Tsunami Medtech, Llc Medical instrument and method of use
US6734018B2 (en) 1999-06-07 2004-05-11 Lifenet Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced
US6312474B1 (en) * 1999-09-15 2001-11-06 Bio-Vascular, Inc. Resorbable implant materials
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8444636B2 (en) 2001-12-07 2013-05-21 Tsunami Medtech, Llc Medical instrument and method of use
US7549987B2 (en) 2000-12-09 2009-06-23 Tsunami Medtech, Llc Thermotherapy device
US9433457B2 (en) 2000-12-09 2016-09-06 Tsunami Medtech, Llc Medical instruments and techniques for thermally-mediated therapies
US6743574B1 (en) 2000-09-12 2004-06-01 Lifenet Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced
US8563232B2 (en) 2000-09-12 2013-10-22 Lifenet Health Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced
US8579892B2 (en) 2003-10-07 2013-11-12 Tsunami Medtech, Llc Medical system and method of use
US7435425B2 (en) 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
DE60204021T2 (en) * 2001-07-26 2006-01-12 Cook Biotech, Inc., West Lafayette Closure device for a vascular and application device
US8465516B2 (en) * 2001-07-26 2013-06-18 Oregon Health Science University Bodily lumen closure apparatus and method
US6878168B2 (en) 2002-01-03 2005-04-12 Edwards Lifesciences Corporation Treatment of bioprosthetic tissues to mitigate post implantation calcification
US8308797B2 (en) 2002-01-04 2012-11-13 Colibri Heart Valve, LLC Percutaneously implantable replacement heart valve device and method of making same
US7128748B2 (en) 2002-03-26 2006-10-31 Synovis Life Technologies, Inc. Circular stapler buttress combination
US20030187515A1 (en) * 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
ES2503550T3 (en) 2002-05-10 2014-10-07 Covidien Lp Surgical stapling device that has a material applicator set for wound closure
US7682392B2 (en) 2002-10-30 2010-03-23 Depuy Spine, Inc. Regenerative implants for stabilizing the spine and devices for attachment of said implants
US7144588B2 (en) * 2003-01-17 2006-12-05 Synovis Life Technologies, Inc. Method of preventing surgical adhesions
PT1484070E (en) * 2003-06-05 2006-05-31 Baxter Int Compositions to repair and regenerate dura-mater humana
US8834864B2 (en) 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
US7927626B2 (en) 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US8337545B2 (en) 2004-02-09 2012-12-25 Cook Medical Technologies Llc Woven implantable device
US20060047291A1 (en) * 2004-08-20 2006-03-02 Uptake Medical Corporation Non-foreign occlusion of an airway and lung collapse
US7455682B2 (en) 2004-10-18 2008-11-25 Tyco Healthcare Group Lp Structure containing wound treatment material
MX2007005937A (en) 2004-11-16 2007-09-11 Robert L Barry Device and method for lung treatment.
US7744621B2 (en) * 2004-12-06 2010-06-29 Cook Incorporated Inflatable occlusion devices, methods, and systems
US20060173470A1 (en) 2005-01-31 2006-08-03 Oray B N Surgical fastener buttress material
US8197534B2 (en) * 2005-03-31 2012-06-12 Cook Medical Technologies Llc Valve device with inflatable chamber
EP1901789A2 (en) * 2005-06-30 2008-03-26 Anthrogenesis Corporation Repair of tympanic membrane using placenta derived collagen biofabric
CN1903143A (en) * 2005-07-29 2007-01-31 广东冠昊生物科技有限公司 Biological type artificial blood vessel and method for preparing the same
CN1903144A (en) * 2005-07-29 2007-01-31 广东冠昊生物科技有限公司 Biological artificial ligamentum and method for preparing same
US20070032785A1 (en) 2005-08-03 2007-02-08 Jennifer Diederich Tissue evacuation device
CN100482178C (en) * 2005-08-04 2009-04-29 广东冠昊生物科技有限公司 Blood vessel tumor clip with biological film
WO2007070301A2 (en) * 2005-12-05 2007-06-21 Regeneration Technologies, Inc. Vascular graft sterilization and decellularization
CN1986007B (en) * 2005-12-20 2011-09-14 广东冠昊生物科技股份有限公司 Biological surgical patch
CN1986006A (en) * 2005-12-20 2007-06-27 广州知光生物科技有限公司 Biological nerve duct
CN1986001B (en) * 2005-12-20 2011-09-14 广东冠昊生物科技股份有限公司 Biological wound-protecting film
CN1985778B (en) * 2005-12-20 2010-10-13 广东冠昊生物科技股份有限公司 Artificial biological cornea
US7670762B2 (en) * 2006-01-17 2010-03-02 Brennen Medical, Llc Biocompatible tissue graft material for implant and method of making
KR20090017654A (en) 2006-05-31 2009-02-18 박스터 헬쓰케어 에스.에이. Method for directed cell in-growth and controlled tissue regeneration in spinal surgery
TWI436793B (en) 2006-08-02 2014-05-11 Baxter Int Rapidly acting dry sealant and methods for use and manufacture
US8105634B2 (en) * 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
US8071135B2 (en) 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
KR20160093739A (en) 2006-10-06 2016-08-08 안트로제네시스 코포레이션 Native(telopeptide) Placental Collagen Compositions
EP2606723B1 (en) 2006-10-27 2014-06-18 Edwards Lifesciences Corporation Biological tissue for surgical implantation
US8585645B2 (en) * 2006-11-13 2013-11-19 Uptake Medical Corp. Treatment with high temperature vapor
US7993323B2 (en) 2006-11-13 2011-08-09 Uptake Medical Corp. High pressure and high temperature vapor catheters and systems
US9101691B2 (en) 2007-06-11 2015-08-11 Edwards Lifesciences Corporation Methods for pre-stressing and capping bioprosthetic tissue
US8932619B2 (en) * 2007-06-27 2015-01-13 Sofradim Production Dural repair material
US20090018655A1 (en) * 2007-07-13 2009-01-15 John Brunelle Composite Implant for Surgical Repair
US9744043B2 (en) 2007-07-16 2017-08-29 Lifenet Health Crafting of cartilage
US20090068250A1 (en) * 2007-09-07 2009-03-12 Philippe Gravagna Bioresorbable and biocompatible compounds for surgical use
CZ301086B6 (en) * 2007-10-17 2009-11-04 Bio-Skin, A. S. Sterile autogenous, allogenic or xenogenic implant and process for preparing thereof
US8322335B2 (en) 2007-10-22 2012-12-04 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
ES2456965T3 (en) 2007-10-22 2014-04-24 Uptake Medical Corp. Determination of the parameters of the steam treatment and administration specific to the patient
TWI461227B (en) * 2007-10-30 2014-11-21 Baxter Int Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects
US9308068B2 (en) 2007-12-03 2016-04-12 Sofradim Production Implant for parastomal hernia
US8357387B2 (en) 2007-12-21 2013-01-22 Edwards Lifesciences Corporation Capping bioprosthetic tissue to reduce calcification
US9924992B2 (en) 2008-02-20 2018-03-27 Tsunami Medtech, Llc Medical system and method of use
JP5569398B2 (en) 2008-02-29 2014-08-13 フェッローサン メディカル ディバイス エー/エス Device for promoting hemostasis and / or wound healing
GB2471632B (en) * 2008-05-02 2012-04-18 Cook Biotech Inc Self deploying SIS in needle
US8579888B2 (en) 2008-06-17 2013-11-12 Tsunami Medtech, Llc Medical probes for the treatment of blood vessels
WO2009156866A2 (en) 2008-06-27 2009-12-30 Sofradim Production Biosynthetic implant for soft tissue repair
CN101332316B (en) * 2008-07-22 2012-12-26 广东冠昊生物科技股份有限公司 Biotype nose bridge implantation body
US20100023129A1 (en) * 2008-07-22 2010-01-28 Guo-Feng Xu Jawbone prosthesis and method of manufacture
CN101332314B (en) * 2008-07-22 2012-11-14 广东冠昊生物科技股份有限公司 Biotype articular cartilage repair piece
US9387280B2 (en) * 2008-09-05 2016-07-12 Synovis Orthopedic And Woundcare, Inc. Device for soft tissue repair or replacement
US8721632B2 (en) 2008-09-09 2014-05-13 Tsunami Medtech, Llc Methods for delivering energy into a target tissue of a body
US10064697B2 (en) 2008-10-06 2018-09-04 Santa Anna Tech Llc Vapor based ablation system for treating various indications
US9561068B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US20100094270A1 (en) 2008-10-06 2010-04-15 Sharma Virender K Method and Apparatus for Tissue Ablation
US9561066B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
EP2427141A4 (en) 2009-05-06 2013-08-21 Hansa Medical Products Inc Self-adjusting medical device
US9039783B2 (en) 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
ES2532428T3 (en) 2009-06-16 2015-03-26 Baxter International Inc hemostatic sponge
US8900223B2 (en) 2009-11-06 2014-12-02 Tsunami Medtech, Llc Tissue ablation systems and methods of use
CA2784432C (en) 2009-12-16 2019-01-15 Baxter Healthcare S.A. Hemostatic sponge
US9161801B2 (en) 2009-12-30 2015-10-20 Tsunami Medtech, Llc Medical system and method of use
SG186837A1 (en) 2010-03-01 2013-02-28 Colibri Heart Valve Llc Percutaneously deliverable heart valve and methods associated therewith
US8679404B2 (en) 2010-03-05 2014-03-25 Edwards Lifesciences Corporation Dry prosthetic heart valve packaging system
NZ602707A (en) 2010-03-23 2014-05-30 Edwards Lifesciences Corp Methods of conditioning sheet bioprosthetic tissue
CN102939113B (en) 2010-04-07 2014-12-24 巴克斯特国际公司 Hemostatic sponge
BR112012030457A2 (en) 2010-06-01 2017-06-20 Baxter Healthcare Sa process for making a dry and stable hesostatic composition, method for delivering a hemostatic composition to a target site and providing a ready-to-use hemostatic composition, finished finished container, and kit for administering a hemostatic composition
WO2011151384A1 (en) 2010-06-01 2011-12-08 Baxter International Inc. Process for making dry and stable hemostatic compositions
JP5968308B2 (en) 2010-06-01 2016-08-10 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated Process for making a dry and stable hemostatic composition
US8906601B2 (en) 2010-06-17 2014-12-09 Edwardss Lifesciences Corporation Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates
CN103153384B (en) 2010-06-28 2016-03-09 科利柏心脏瓣膜有限责任公司 Conveyor means within the blood vessel through the lumen of the device for
WO2012064864A1 (en) 2010-11-09 2012-05-18 Aegea Medical Inc. Positioning method and apparatus for delivering vapor to the uterus
US9351829B2 (en) 2010-11-17 2016-05-31 Edwards Lifesciences Corporation Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability
SG10201601962WA (en) 2010-12-14 2016-04-28 Colibri Heart Valve Llc Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets
US9498317B2 (en) 2010-12-16 2016-11-22 Edwards Lifesciences Corporation Prosthetic heart valve delivery systems and packaging
FR2972626B1 (en) 2011-03-16 2014-04-11 Sofradim Production Prosthetic comprising a three-dimensional knit and adjusted
US8965499B2 (en) 2011-04-29 2015-02-24 Cyberonics, Inc. Overwrap for nerve stimulation system
FR2977790B1 (en) 2011-07-13 2013-07-19 Sofradim Production Prosthetic for umbilic hernia
FR2977789B1 (en) 2011-07-13 2013-07-19 Sofradim Production Prosthetic for umbilic hernia
US8998059B2 (en) 2011-08-01 2015-04-07 Ethicon Endo-Surgery, Inc. Adjunct therapy device having driver with cavity for hemostatic agent
US9549715B2 (en) 2011-08-09 2017-01-24 Cook Regentec Llc Vial useable in tissue extraction procedures
US9492170B2 (en) 2011-08-10 2016-11-15 Ethicon Endo-Surgery, Inc. Device for applying adjunct in endoscopic procedure
US8998060B2 (en) 2011-09-13 2015-04-07 Ethicon Endo-Surgery, Inc. Resistive heated surgical staple cartridge with phase change sealant
US9101359B2 (en) 2011-09-13 2015-08-11 Ethicon Endo-Surgery, Inc. Surgical staple cartridge with self-dispensing staple buttress
US9999408B2 (en) 2011-09-14 2018-06-19 Ethicon Endo-Surgery, Inc. Surgical instrument with fluid fillable buttress
US9254180B2 (en) 2011-09-15 2016-02-09 Ethicon Endo-Surgery, Inc. Surgical instrument with staple reinforcement clip
US8814025B2 (en) 2011-09-15 2014-08-26 Ethicon Endo-Surgery, Inc. Fibrin pad matrix with suspended heat activated beads of adhesive
US9125649B2 (en) 2011-09-15 2015-09-08 Ethicon Endo-Surgery, Inc. Surgical instrument with filled staple
US9198644B2 (en) 2011-09-22 2015-12-01 Ethicon Endo-Surgery, Inc. Anvil cartridge for surgical fastening device
US9393018B2 (en) 2011-09-22 2016-07-19 Ethicon Endo-Surgery, Inc. Surgical staple assembly with hemostatic feature
US8985429B2 (en) 2011-09-23 2015-03-24 Ethicon Endo-Surgery, Inc. Surgical stapling device with adjunct material application feature
CN103781499B (en) 2011-09-30 2016-09-28 索弗拉狄姆产品公司 Reversible hardened lightweight web
EP2760431A1 (en) 2011-09-30 2014-08-06 Sofradim Production Multilayer implants for delivery of therapeutic agents
US8899464B2 (en) 2011-10-03 2014-12-02 Ethicon Endo-Surgery, Inc. Attachment of surgical staple buttress to cartridge
US9089326B2 (en) 2011-10-07 2015-07-28 Ethicon Endo-Surgery, Inc. Dual staple cartridge for surgical stapler
CN103957949B (en) 2011-10-11 2017-07-18 巴克斯特国际公司 Hemostatic composition
WO2013053755A2 (en) 2011-10-11 2013-04-18 Baxter International Inc. Hemostatic compositions
TWI548417B (en) 2011-10-27 2016-09-11 Baxter Int Hemostatic composition
US9162011B2 (en) 2011-12-19 2015-10-20 Allosource Flowable matrix compositions and methods
FR2985271B1 (en) 2011-12-29 2014-01-24 Sofradim Production Knitted picots
FR2985170B1 (en) 2011-12-29 2014-01-24 Sofradim Production Prosthesis for inguinal hernia
WO2013185776A1 (en) 2012-06-12 2013-12-19 Ferrosan Medical Devices A/S Dry haemostatic composition
US20140005793A1 (en) * 2012-06-21 2014-01-02 Keith Cameron Koford Novel biological implant compositions, implants and methods
FR2994185B1 (en) 2012-08-02 2015-07-31 Sofradim Production Process for the preparation of a porous chitosan layer
FR2995779B1 (en) 2012-09-25 2015-09-25 Sofradim Production Prosthetic comprising a treillis and a means of consolidation
FR2995778B1 (en) 2012-09-25 2015-06-26 Sofradim Production Abdominal wall reinforcing prosthesis and method for manufacturing the same
FR2995788B1 (en) 2012-09-25 2014-09-26 Sofradim Production Hemostatic patch and preparation method
US10159555B2 (en) 2012-09-28 2018-12-25 Sofradim Production Packaging for a hernia repair device
US10238771B2 (en) 2012-11-08 2019-03-26 Edwards Lifesciences Corporation Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system
WO2014113724A2 (en) 2013-01-17 2014-07-24 Sharma Virender K Method and apparatus for tissue ablation
US9943353B2 (en) 2013-03-15 2018-04-17 Tsunami Medtech, Llc Medical system and method of use
FR3006581B1 (en) 2013-06-07 2016-07-22 Sofradim Production Prosthesis based on textile for laparoscopic pathway
FR3006578B1 (en) 2013-06-07 2015-05-29 Sofradim Production Prosthesis based on textile for laparoscopic pathway
JP6390873B2 (en) 2013-06-21 2018-09-19 フェッローサン メディカル ディバイス エー/エス Dry composition expanded under reduced pressure and syringe for holding the same
US9615922B2 (en) 2013-09-30 2017-04-11 Edwards Lifesciences Corporation Method and apparatus for preparing a contoured biological tissue
US9782211B2 (en) 2013-10-01 2017-10-10 Uptake Medical Technology Inc. Preferential volume reduction of diseased segments of a heterogeneous lobe
RU2678592C1 (en) 2013-12-11 2019-01-30 Ферросан Медикал Дивайсиз А/С Dry composition comprising extrusion enhancer
CN106794030B (en) 2014-05-22 2019-09-03 埃杰亚医疗公司 System and method for executing endometrial ablation
WO2015179662A1 (en) 2014-05-22 2015-11-26 Aegea Medical Inc. Integrity testing method and apparatus for delivering vapor to the uterus
EP3000432A1 (en) 2014-09-29 2016-03-30 Sofradim Production Textile-based prosthesis for treatment of inguinal hernia
EP3000433A1 (en) 2014-09-29 2016-03-30 Sofradim Production Device for introducing a prosthesis for hernia treatment into an incision
EP3029189A1 (en) 2014-12-05 2016-06-08 Sofradim Production Prosthetic porous knit, method of making same and hernia prosthesis
EP3059255A1 (en) 2015-02-17 2016-08-24 Sofradim Production Method for preparing a chitosan-based matrix comprising a fiber reinforcement member
EP3085337A1 (en) 2015-04-24 2016-10-26 Sofradim Production Prosthesis for supporting a breast structure
WO2018007849A1 (en) * 2016-07-05 2018-01-11 Carlos Alvarado Serous membrane for ocular surface disorders
USD845467S1 (en) 2017-09-17 2019-04-09 Uptake Medical Technology Inc. Hand-piece for medical ablation catheter

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991184A (en) * 1973-10-05 1976-11-09 Martin Kludas Agent for the care of skin
US4915113A (en) * 1988-12-16 1990-04-10 Bio-Vascular, Inc. Method and apparatus for monitoring the patency of vascular grafts
US5085629A (en) * 1988-10-06 1992-02-04 Medical Engineering Corporation Biodegradable stent
US5306286A (en) * 1987-06-25 1994-04-26 Duke University Absorbable stent
US5376112A (en) * 1992-01-27 1994-12-27 Duran; Carlos G. Valveless conduit with sigmoid valve annuloplasty ring
US5411965A (en) * 1993-08-23 1995-05-02 Arizona Board Of Regents Use of delta opioid receptor antagonists to treat cocaine abuse
US5413798A (en) * 1988-10-15 1995-05-09 B. Braun Melsungen Aktiengesellschaft Process for preparing bovine pericard materials and use thereof
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5503638A (en) * 1994-02-10 1996-04-02 Bio-Vascular, Inc. Soft tissue stapling buttress
US5599852A (en) * 1994-10-18 1997-02-04 Ethicon, Inc. Injectable microdispersions for soft tissue repair and augmentation
US5634946A (en) * 1988-08-24 1997-06-03 Focal, Inc. Polymeric endoluminal paving process
US5752965A (en) * 1996-10-21 1998-05-19 Bio-Vascular, Inc. Apparatus and method for producing a reinforced surgical fastener suture line
US5783214A (en) * 1994-06-13 1998-07-21 Buford Biomedical, Inc. Bio-erodible matrix for the controlled release of medicinals
US5830915A (en) * 1996-08-28 1998-11-03 The Procter & Gamble Company Phosphinic acid amides as matrix metalloprotease inhibitors
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5837278A (en) * 1994-01-06 1998-11-17 Ed Geistlich Sohne Ag Fur Chemische Industrie Resorbable collagen membrane for use in guided tissue regeneration
US5895420A (en) * 1995-06-07 1999-04-20 St. Jude Medical, Inc. Bioresorbable heart valve support
US6187048B1 (en) * 1994-05-24 2001-02-13 Surgical Dynamics, Inc. Intervertebral disc implant
US6652594B2 (en) * 1999-09-15 2003-11-25 Synovis Life Technologies, Inc. Resorbable implant materials

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4724199B1 (en) * 1969-11-17 1972-07-04
JPH0679616B2 (en) * 1985-07-25 1994-10-12 株式会社高研 Crosslinked Medical supplies
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5932236A (en) 1997-03-06 1999-08-03 Bass; James S. Pharmaceutical composition and methods for using it
WO1998052619A2 (en) * 1997-05-22 1998-11-26 Merck Patent Gmbh Peptide-coated implants and methods for producing same
US6166184A (en) * 1997-08-18 2000-12-26 Medtronic Inc. Process for making a bioprosthetic device
WO1999048540A1 (en) 1998-03-23 1999-09-30 Bio-Vascular, Inc. Implants and method of making
US6106555A (en) * 1998-12-15 2000-08-22 Av Healing Llc Method for tissue fixation
US6274635B1 (en) * 1999-03-22 2001-08-14 Immugen Pharmaceuticals Inc. Alkylated resorcinol derivatives for the treatment of immune diseases
WO2001000920A1 (en) * 1999-06-25 2001-01-04 Kaneka Corporation Regenerated collagen fiber reduced in odor and improved in suitability for setting, process for producing the same, and method of setting

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991184A (en) * 1973-10-05 1976-11-09 Martin Kludas Agent for the care of skin
US5306286A (en) * 1987-06-25 1994-04-26 Duke University Absorbable stent
US5634946A (en) * 1988-08-24 1997-06-03 Focal, Inc. Polymeric endoluminal paving process
US5085629A (en) * 1988-10-06 1992-02-04 Medical Engineering Corporation Biodegradable stent
US5413798A (en) * 1988-10-15 1995-05-09 B. Braun Melsungen Aktiengesellschaft Process for preparing bovine pericard materials and use thereof
US4915113A (en) * 1988-12-16 1990-04-10 Bio-Vascular, Inc. Method and apparatus for monitoring the patency of vascular grafts
US5376112A (en) * 1992-01-27 1994-12-27 Duran; Carlos G. Valveless conduit with sigmoid valve annuloplasty ring
US5411965A (en) * 1993-08-23 1995-05-02 Arizona Board Of Regents Use of delta opioid receptor antagonists to treat cocaine abuse
US5837278A (en) * 1994-01-06 1998-11-17 Ed Geistlich Sohne Ag Fur Chemische Industrie Resorbable collagen membrane for use in guided tissue regeneration
US5503638A (en) * 1994-02-10 1996-04-02 Bio-Vascular, Inc. Soft tissue stapling buttress
US5549628A (en) * 1994-02-10 1996-08-27 Bio-Vascular, Inc. Soft tissue stapling buttress
US5575803A (en) * 1994-02-10 1996-11-19 Bio-Vascular, Inc. Soft tissue stapling buttress
US6187048B1 (en) * 1994-05-24 2001-02-13 Surgical Dynamics, Inc. Intervertebral disc implant
US5783214A (en) * 1994-06-13 1998-07-21 Buford Biomedical, Inc. Bio-erodible matrix for the controlled release of medicinals
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5599852A (en) * 1994-10-18 1997-02-04 Ethicon, Inc. Injectable microdispersions for soft tissue repair and augmentation
US5895420A (en) * 1995-06-07 1999-04-20 St. Jude Medical, Inc. Bioresorbable heart valve support
US5830915A (en) * 1996-08-28 1998-11-03 The Procter & Gamble Company Phosphinic acid amides as matrix metalloprotease inhibitors
US5752965A (en) * 1996-10-21 1998-05-19 Bio-Vascular, Inc. Apparatus and method for producing a reinforced surgical fastener suture line
US6652594B2 (en) * 1999-09-15 2003-11-25 Synovis Life Technologies, Inc. Resorbable implant materials

Cited By (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951166B2 (en) 2002-06-17 2011-05-31 Tyco Healthcare Group Lp Annular support structures
US7744627B2 (en) 2002-06-17 2010-06-29 Tyco Healthcare Group Lp Annular support structures
US8257391B2 (en) 2002-06-17 2012-09-04 Tyco Healthcare Group Lp Annular support structures
US9351729B2 (en) 2002-06-17 2016-05-31 Covidien Lp Annular support structures
US8551138B2 (en) 2002-06-17 2013-10-08 Covidien Lp Annular support structures
US20050245965A1 (en) * 2002-06-17 2005-11-03 Orban Iii Joseph P Annular support structures
US20080110959A1 (en) * 2002-06-17 2008-05-15 Tyco Healthcare Group Lp Annular support structures
US20110130788A1 (en) * 2002-06-17 2011-06-02 Tyco Healthcare Group Lp Annular support structures
US8192460B2 (en) 2002-06-17 2012-06-05 Tyco Healthcare Group Lp Annular support structures
US20080140115A1 (en) * 2004-08-17 2008-06-12 Stopek Joshua B Stapling Support Structures
US9028528B2 (en) 2004-10-15 2015-05-12 Covidien Lp Seal element for anastomosis
US9737304B2 (en) 2004-10-15 2017-08-22 Covidien Lp Seal element for anastomosis
US20100282814A1 (en) * 2004-10-15 2010-11-11 Tyco Healthcaere Group LP Seal Element for Anastomosis
US8663258B2 (en) 2004-10-15 2014-03-04 Covidien Lp Seal element for anastomosis
US20060085030A1 (en) * 2004-10-15 2006-04-20 Bettuchi Michael J Seal element for anastomosis
US8372094B2 (en) 2004-10-15 2013-02-12 Covidien Lp Seal element for anastomosis
US8236015B2 (en) 2004-10-15 2012-08-07 Tyco Healthcare Group Lp Seal element for anastomosis
US8308045B2 (en) 2004-10-18 2012-11-13 Tyco Healthcare Group Lp Annular adhesive structure
US8225799B2 (en) 2004-10-18 2012-07-24 Tyco Healthcare Group Lp Support structures and methods of using the same
US10154840B2 (en) 2004-10-18 2018-12-18 Covidien Lp Annular adhesive structure
US8312885B2 (en) 2004-10-18 2012-11-20 Tyco Healthcare Group Lp Annular adhesive structure
US8146791B2 (en) 2004-10-18 2012-04-03 Tyco Healthcare Group Lp Annular adhesive structure
US8313014B2 (en) 2004-10-18 2012-11-20 Covidien Lp Support structures and methods of using the same
US8684250B2 (en) 2004-10-18 2014-04-01 Covidien Lp Annular adhesive structure
US9445817B2 (en) 2004-10-18 2016-09-20 Covidien Lp Support structures and methods of using the same
US8511533B2 (en) 2004-10-18 2013-08-20 Covidien Lp Annular adhesive structure
US8424742B2 (en) 2004-10-18 2013-04-23 Covidien Lp Support structures and methods of using the same
US7823592B2 (en) 2004-10-18 2010-11-02 Tyco Healthcare Group Lp Annular adhesive structure
US20100282815A1 (en) * 2004-10-18 2010-11-11 Tyco Healthcare Group Lp Annular Adhesive Structure
US9220504B2 (en) 2004-10-18 2015-12-29 Covidien Lp Annular adhesive structure
US20060135992A1 (en) * 2004-10-18 2006-06-22 Bettuchi Michael J Annular adhesive structure
US7845536B2 (en) 2004-10-18 2010-12-07 Tyco Healthcare Group Lp Annular adhesive structure
US20110036894A1 (en) * 2004-10-18 2011-02-17 Tyco Healthcare Group Lp Support structures and methods of using the same
US20060085034A1 (en) * 2004-10-18 2006-04-20 Bettuchi Michael J Support structures and methods of using the same
US7938307B2 (en) 2004-10-18 2011-05-10 Tyco Healthcare Group Lp Support structures and methods of using the same
US8276800B2 (en) 2004-10-18 2012-10-02 Tyco Healthcare Group Lp Support structures and methods of using the same
US8167895B2 (en) 2005-03-15 2012-05-01 Tyco Healthcare Group Lp Anastomosis composite gasket
US9226754B2 (en) 2005-03-15 2016-01-05 Covidien Lp Anastomosis composite gasket
US9364229B2 (en) 2005-03-15 2016-06-14 Covidien Lp Circular anastomosis structures
US20100012703A1 (en) * 2005-05-05 2010-01-21 Allison Calabrese Surgical Gasket
US9629626B2 (en) 2006-02-02 2017-04-25 Covidien Lp Mechanically tuned buttress material to assist with proper formation of surgical element in diseased tissue
US20070203509A1 (en) * 2006-02-28 2007-08-30 Bettuchi Michael J Hub for positioning annular structure on a surgical device
US8286849B2 (en) 2006-02-28 2012-10-16 Tyco Healthcare Group Lp Hub for positioning annular structure on a surgical device
US7793813B2 (en) 2006-02-28 2010-09-14 Tyco Healthcare Group Lp Hub for positioning annular structure on a surgical device
US20070203510A1 (en) * 2006-02-28 2007-08-30 Bettuchi Michael J Annular disk for reduction of anastomotic tension and methods of using the same
US9161757B2 (en) 2006-02-28 2015-10-20 Covidien Lp Hub for positioning annular structure on a surgical device
US9433413B2 (en) 2006-10-26 2016-09-06 Covidien Lp Methods of using shape memory alloys for buttress attachment
US8453652B2 (en) 2006-10-26 2013-06-04 Covidien Lp Methods of using shape memory alloys for buttress attachment
US20100065606A1 (en) * 2006-10-26 2010-03-18 Stopek Megan L Methods of Using Shape Memory Alloys for Buttress Attachment
US8028883B2 (en) 2006-10-26 2011-10-04 Tyco Healthcare Group Lp Methods of using shape memory alloys for buttress attachment
US8245901B2 (en) 2006-10-26 2012-08-21 Tyco Healthcare Group Lp Methods of using shape memory alloys for buttress attachment
US8011555B2 (en) 2007-03-06 2011-09-06 Tyco Healthcare Group Lp Surgical stapling apparatus
US8371492B2 (en) 2007-03-06 2013-02-12 Covidien Lp Surgical stapling apparatus
US10111659B2 (en) 2007-03-06 2018-10-30 Covidien Lp Surgical stapling apparatus
US20090134200A1 (en) * 2007-03-06 2009-05-28 Danyel Tarinelli Surgical stapling apparatus
US20100072254A1 (en) * 2007-03-06 2010-03-25 Tyco Healthcare Group Lp Surgical stapling apparatus
US8231043B2 (en) 2007-03-06 2012-07-31 Tyco Healthcare Group Lp Surgical stapling apparatus
US9192379B2 (en) 2007-03-06 2015-11-24 Covidien Lp Surgical stapling apparatus
US9345479B2 (en) 2007-03-06 2016-05-24 Covidien Lp Surgical stapling apparatus
US9192378B2 (en) 2007-03-06 2015-11-24 Covidien Lp Surgical stapling apparatus
US8413871B2 (en) 2007-03-06 2013-04-09 Covidien Lp Surgical stapling apparatus
US9192380B2 (en) 2007-03-06 2015-11-24 Covidien Lp Surgical stapling apparatus
US8371493B2 (en) 2007-03-06 2013-02-12 Covidien Lp Surgical stapling apparatus
US20100012704A1 (en) * 2007-03-06 2010-01-21 Danyel Tarinelli Racenet Surgical Stapling Apparatus
US8256654B2 (en) 2007-05-25 2012-09-04 Tyco Healthcare Group Lp Staple buttress retention system
US8016177B2 (en) 2007-05-25 2011-09-13 Tyco Healthcare Group Lp Staple buttress retention system
US9433412B2 (en) 2007-05-25 2016-09-06 Covidien Lp Staple buttress retention system
US9775618B2 (en) 2007-05-25 2017-10-03 Covidien Lp Staple buttress retention system
US8453910B2 (en) 2007-05-25 2013-06-04 Covidien Lp Staple buttress retention system
US8210414B2 (en) 2007-05-25 2012-07-03 Tyco Healthcare Group Lp Staple buttress retention system
US8038045B2 (en) 2007-05-25 2011-10-18 Tyco Healthcare Group Lp Staple buttress retention system
US8083119B2 (en) 2007-06-18 2011-12-27 Tyco Healthcare Group Lp Interlocking buttress material retention system
US7665646B2 (en) 2007-06-18 2010-02-23 Tyco Healthcare Group Lp Interlocking buttress material retention system
US8308042B2 (en) 2007-06-18 2012-11-13 Tyco Healthcare Group Lp Structure for attachment of buttress material to anvils and cartridges of surgical stapler
US20080308608A1 (en) * 2007-06-18 2008-12-18 Prommersberger Megan L Interlocking buttress material retention system
US8308046B2 (en) 2007-06-18 2012-11-13 Tyco Healthcare Group Lp Interlocking buttress material retention system
US9016543B2 (en) 2007-06-18 2015-04-28 Covidien Lp Interlocking buttress material retention system
US9364234B2 (en) 2007-06-18 2016-06-14 Covidien Lp Interlocking buttress material retention system
US20100116868A1 (en) * 2007-06-18 2010-05-13 Tyco Healthcare Group Lp Interlocking buttress material retention system
US8616430B2 (en) 2007-06-18 2013-12-31 Covidien Lp Interlocking buttress material retention system
US7909224B2 (en) 2007-06-18 2011-03-22 Tyco Healthcare Group Lp Interlocking buttress material retention system
US20110215133A1 (en) * 2007-06-18 2011-09-08 Tyco Healthcare Group Lp Structure for attachment of buttress material to anvils and cartridges of surgical stapler
US20090218384A1 (en) * 2007-06-18 2009-09-03 Ernie Aranyi Structure for attachment of buttress material to anvils and cartridges of surgical staplers
US7950561B2 (en) 2007-06-18 2011-05-31 Tyco Healthcare Group Lp Structure for attachment of buttress material to anvils and cartridges of surgical staplers
US10022125B2 (en) 2007-06-18 2018-07-17 Covidien Lp Interlocking buttress material retention system
US9198663B1 (en) 2007-06-22 2015-12-01 Covidien Lp Detachable buttress material retention systems for use with a surgical stapling device
US9113873B2 (en) 2007-06-22 2015-08-25 Covidien Lp Detachable buttress material retention systems for use with a surgical stapling device
US20080314960A1 (en) * 2007-06-22 2008-12-25 Stanislaw Marczyk Detachable buttress material retention systems for use with a surgical stapling device
US7845533B2 (en) 2007-06-22 2010-12-07 Tyco Healthcare Group Lp Detachable buttress material retention systems for use with a surgical stapling device
US8512402B2 (en) 2007-06-22 2013-08-20 Covidien Lp Detachable buttress material retention systems for use with a surgical stapling device
US8496683B2 (en) 2007-06-27 2013-07-30 Covidien Lp Buttress and surgical stapling apparatus
US9005243B2 (en) 2007-06-27 2015-04-14 Covidien Lp Buttress and surgical stapling apparatus
US20090001122A1 (en) * 2007-06-27 2009-01-01 Megan Prommersberger Buttress and surgical stapling apparatus
US8062330B2 (en) 2007-06-27 2011-11-22 Tyco Healthcare Group Lp Buttress and surgical stapling apparatus
US9636850B2 (en) 2007-06-27 2017-05-02 Covidien Lp Buttress and surgical stapling apparatus
US20090054995A1 (en) * 2007-07-24 2009-02-26 Aesculap Ag, A Corporation Of Germany Planar implant
US9370604B2 (en) * 2007-07-24 2016-06-21 Aesculap Ag Planar implant
US20100082114A1 (en) * 2008-04-29 2010-04-01 Peter Gingras Tissue repair implant
US9468702B2 (en) 2008-04-29 2016-10-18 Proxy Biomedical Limited Tissue repair implant
US20100082113A1 (en) * 2008-04-29 2010-04-01 Peter Gingras Tissue repair implant
US8709096B2 (en) 2008-04-29 2014-04-29 Proxy Biomedical Limited Tissue repair implant
US10220114B2 (en) 2008-04-29 2019-03-05 Proxy Biomedical Limited Tissue repair implant
US8668129B2 (en) 2008-12-16 2014-03-11 Covidien Lp Surgical apparatus including surgical buttress
US8365972B2 (en) 2009-03-31 2013-02-05 Covidien Lp Surgical stapling apparatus
US9010606B2 (en) 2009-03-31 2015-04-21 Covidien Lp Surgical stapling apparatus
US8235273B2 (en) 2009-03-31 2012-08-07 Tyco Healthcare Group Lp Center cinch and release of buttress material
US20100249805A1 (en) * 2009-03-31 2010-09-30 Lee Olson Crimp And Release Of Suture Holding Buttress Material
US20100243708A1 (en) * 2009-03-31 2010-09-30 Ernie Aranyi Surgical stapling apparatus
US8939344B2 (en) 2009-03-31 2015-01-27 Covidien Lp Surgical stapling apparatus
US20100243707A1 (en) * 2009-03-31 2010-09-30 Lee Olson Surgical stapling apparatus
US8408440B2 (en) 2009-03-31 2013-04-02 Covidien Lp Surgical stapling apparatus
US7967179B2 (en) 2009-03-31 2011-06-28 Tyco Healthcare Group Lp Center cinch and release of buttress material
US8757466B2 (en) 2009-03-31 2014-06-24 Covidien Lp Surgical stapling apparatus
US8016178B2 (en) 2009-03-31 2011-09-13 Tyco Healthcare Group Lp Surgical stapling apparatus
US8453909B2 (en) 2009-03-31 2013-06-04 Covidien Lp Center cinch and release of buttress material
US8348126B2 (en) 2009-03-31 2013-01-08 Covidien Lp Crimp and release of suture holding buttress material
US9486215B2 (en) 2009-03-31 2016-11-08 Covidien Lp Surgical stapling apparatus
US10327772B2 (en) 2009-03-31 2019-06-25 Covidien Lp Center cinch and release of buttress material
US10368869B2 (en) 2009-03-31 2019-08-06 Covidien Lp Surgical stapling apparatus
US8011550B2 (en) 2009-03-31 2011-09-06 Tyco Healthcare Group Lp Surgical stapling apparatus
US9445812B2 (en) 2009-03-31 2016-09-20 Covidien Lp Center cinch and release of buttress material
US8157149B2 (en) 2009-03-31 2012-04-17 Tyco Healthcare Group Lp Crimp and release of suture holding buttress material
US7988027B2 (en) 2009-03-31 2011-08-02 Tyco Healthcare Group Lp Crimp and release of suture holding buttress material
US8631989B2 (en) 2009-03-31 2014-01-21 Covidien Lp Surgical stapling apparatus
US8561873B2 (en) 2009-10-15 2013-10-22 Covidien Lp Staple line reinforcement for anvil and cartridge
US9622745B2 (en) 2009-10-15 2017-04-18 Covidien Lp Staple line reinforcement for anvil and cartridge
US9693772B2 (en) 2009-10-15 2017-07-04 Covidien Lp Staple line reinforcement for anvil and cartridge
US10293553B2 (en) 2009-10-15 2019-05-21 Covidien Lp Buttress brachytherapy and integrated staple line markers for margin identification
US8157151B2 (en) 2009-10-15 2012-04-17 Tyco Healthcare Group Lp Staple line reinforcement for anvil and cartridge
US9610080B2 (en) 2009-10-15 2017-04-04 Covidien Lp Staple line reinforcement for anvil and cartridge
US8348130B2 (en) 2010-12-10 2013-01-08 Covidien Lp Surgical apparatus including surgical buttress
US9084602B2 (en) 2011-01-26 2015-07-21 Covidien Lp Buttress film with hemostatic action for surgical stapling apparatus
US9107665B2 (en) 2011-03-10 2015-08-18 Covidien Lp Surgical instrument buttress attachment
US9055944B2 (en) 2011-03-10 2015-06-16 Covidien Lp Surgical instrument buttress attachment
US8479968B2 (en) 2011-03-10 2013-07-09 Covidien Lp Surgical instrument buttress attachment
US8789737B2 (en) 2011-04-27 2014-07-29 Covidien Lp Circular stapler and staple line reinforcement material
US9016544B2 (en) 2011-04-27 2015-04-28 Covidien Lp Circular stapler and staple line reinforcement material
US9675351B2 (en) 2011-10-26 2017-06-13 Covidien Lp Buttress release from surgical stapler by knife pushing
US9107667B2 (en) 2011-11-04 2015-08-18 Covidien Lp Surgical stapling apparatus including releasable buttress
US8870050B2 (en) 2011-11-04 2014-10-28 Covidien Lp Surgical stapling apparatus including releasable buttress
US9010608B2 (en) 2011-12-14 2015-04-21 Covidien Lp Releasable buttress retention on a surgical stapler
US10321908B2 (en) 2011-12-14 2019-06-18 Covidien Lp Surgical stapling apparatus including buttress attachment via tabs
US10357249B2 (en) 2011-12-14 2019-07-23 Covidien Lp Surgical stapling apparatus including releasable surgical buttress
US10098639B2 (en) 2011-12-14 2018-10-16 Covidien Lp Buttress attachment to the cartridge surface
US9237892B2 (en) 2011-12-14 2016-01-19 Covidien Lp Buttress attachment to the cartridge surface
US9351732B2 (en) 2011-12-14 2016-05-31 Covidien Lp Buttress attachment to degradable polymer zones
US9351731B2 (en) 2011-12-14 2016-05-31 Covidien Lp Surgical stapling apparatus including releasable surgical buttress
US9237893B2 (en) 2011-12-14 2016-01-19 Covidien Lp Surgical stapling apparatus including buttress attachment via tabs
US9597077B2 (en) 2011-12-14 2017-03-21 Covidien Lp Buttress attachment to the cartridge surface
US8967448B2 (en) 2011-12-14 2015-03-03 Covidien Lp Surgical stapling apparatus including buttress attachment via tabs
US9113885B2 (en) 2011-12-14 2015-08-25 Covidien Lp Buttress assembly for use with surgical stapling device
US9277922B2 (en) 2011-12-14 2016-03-08 Covidien Lp Surgical stapling apparatus including buttress attachment via tabs
US9775617B2 (en) 2012-01-26 2017-10-03 Covidien Lp Circular stapler including buttress
US9326773B2 (en) 2012-01-26 2016-05-03 Covidien Lp Surgical device including buttress material
US9010609B2 (en) 2012-01-26 2015-04-21 Covidien Lp Circular stapler including buttress
US9010612B2 (en) 2012-01-26 2015-04-21 Covidien Lp Buttress support design for EEA anvil
US9186144B2 (en) 2012-01-26 2015-11-17 Covidien Lp Buttress support design for EEA anvil
US9931116B2 (en) 2012-02-10 2018-04-03 Covidien Lp Buttress composition
US9010610B2 (en) 2012-02-24 2015-04-21 Covidien Lp Buttress retention system for linear endostaplers
US9198660B2 (en) 2012-02-24 2015-12-01 Covidien Lp Buttress retention system for linear endostaplers
US8820606B2 (en) 2012-02-24 2014-09-02 Covidien Lp Buttress retention system for linear endostaplers
US9572576B2 (en) 2012-07-18 2017-02-21 Covidien Lp Surgical apparatus including surgical buttress
US9161753B2 (en) 2012-10-10 2015-10-20 Covidien Lp Buttress fixation for a circular stapler
US10285704B2 (en) 2012-10-10 2019-05-14 Covidien Lp Buttress fixation for a circular stapler
US10420556B2 (en) 2012-11-09 2019-09-24 Covidien Lp Surgical stapling apparatus including buttress attachment
US9192384B2 (en) 2012-11-09 2015-11-24 Covidien Lp Recessed groove for better suture retention
US9681936B2 (en) 2012-11-30 2017-06-20 Covidien Lp Multi-layer porous film material
US9295466B2 (en) 2012-11-30 2016-03-29 Covidien Lp Surgical apparatus including surgical buttress
US10390827B2 (en) 2012-11-30 2019-08-27 Covidien Lp Multi-layer porous film material
US10245031B2 (en) 2012-11-30 2019-04-02 Covidien Lp Surgical apparatus including surgical buttress
US10349942B2 (en) 2012-12-13 2019-07-16 Covidien Lp Folded buttress for use with a surgical apparatus
US9522002B2 (en) 2012-12-13 2016-12-20 Covidien Lp Surgical instrument with pressure distribution device
US9402627B2 (en) 2012-12-13 2016-08-02 Covidien Lp Folded buttress for use with a surgical apparatus
US9204881B2 (en) 2013-01-11 2015-12-08 Covidien Lp Buttress retainer for EEA anvil
US9974542B2 (en) 2013-01-23 2018-05-22 Covidien Lp Surgical apparatus including surgical buttress
US9433420B2 (en) 2013-01-23 2016-09-06 Covidien Lp Surgical apparatus including surgical buttress
US9895151B2 (en) 2013-02-04 2018-02-20 Covidien Lp Circular stapling device including buttress material
US9414839B2 (en) 2013-02-04 2016-08-16 Covidien Lp Buttress attachment for circular stapling device
US9192383B2 (en) 2013-02-04 2015-11-24 Covidien Lp Circular stapling device including buttress material
US10321911B2 (en) 2013-02-25 2019-06-18 Covidien Lp Circular stapling device with buttress
US9504470B2 (en) 2013-02-25 2016-11-29 Covidien Lp Circular stapling device with buttress
US9782173B2 (en) 2013-03-07 2017-10-10 Covidien Lp Circular stapling device including buttress release mechanism
US9655620B2 (en) 2013-10-28 2017-05-23 Covidien Lp Circular surgical stapling device including buttress material
US9844378B2 (en) 2014-04-29 2017-12-19 Covidien Lp Surgical stapling apparatus and methods of adhering a surgical buttress thereto
US10368868B2 (en) 2017-03-09 2019-08-06 Covidien Lp Structure for attaching buttress material to anvil and cartridge of surgical stapling instrument

Also Published As

Publication number Publication date
JP2012040415A (en) 2012-03-01
US6652594B2 (en) 2003-11-25
AU772182B2 (en) 2004-04-08
EP1212105A1 (en) 2002-06-12
ES2220530T3 (en) 2004-12-16
JP2003509129A (en) 2003-03-11
WO2001019423A1 (en) 2001-03-22
AU7131400A (en) 2001-04-17
AT265241T (en) 2004-05-15
CA2384961C (en) 2011-03-29
DE60010287D1 (en) 2004-06-03
CA2384961A1 (en) 2001-03-22
EP1212105B1 (en) 2004-04-28
JP5362937B2 (en) 2013-12-11
US20020138152A1 (en) 2002-09-26
DE60010287T2 (en) 2004-09-23
US6312474B1 (en) 2001-11-06

Similar Documents

Publication Publication Date Title
AU783780B2 (en) Tissue graft
US7745217B2 (en) Graft prosthesis devices containing renal capsule collagen
ES2710024T3 (en) Biotech of collagen and use of it
US8834864B2 (en) Methods for repairing and regenerating human dura mater
US5733337A (en) Tissue repair fabric
US5782914A (en) Method for preparing heterogeneous tissue grafts
CA2525405C (en) Compositions for repairing and regenerating human dura mater
US5782915A (en) Articular cartilage heterografts
CN1088382C (en) Material for medical use and process for preapring same
EP0786970B1 (en) Calcification-resistant bioprosthetic tissue and methods of making same
US7029434B2 (en) Methods for treating implantable biological tissues to mitigate post—implantation calcification
EP2647393B1 (en) Capping bioprosthetic tissue to reduce calcification
AU760114B2 (en) Process for reducing mineralization of tissue used in transplantation
CA1234653A (en) Biomaterial
AU2007325460B2 (en) Processed ECM materials with enhanced component profiles
US20060154230A1 (en) Methods for processing biological tissue
US5595571A (en) Biological material pre-fixation treatment
US20040121951A1 (en) Use of hydrophobic crosslinking agents to prepare crosslinked biomaterial compositions
US4947840A (en) Biodegradable templates for the regeneration of tissues
US5879383A (en) Blood contact surfaces using endothelium on a subendothelial matrix
JP5538217B2 (en) Cell-free tissue matrix construct for tissue repair
EP0744970B1 (en) Improved process for fixation of calcification-resistant biological tissue
US20020087211A1 (en) Anterior cruciate ligament xenografts
Hodde et al. Effects of sterilization on an extracellular matrix scaffold: part I. Composition and matrix architecture
CA2731374C (en) Tissue scaffolds derived from forestomach extracellular matrix

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION